About Codon Capital
Codon Capital is a venture capital firm founded in 2013. It is primarily based out of San Francisco, United States. As of Jan 2026, Codon Capital has invested in 31 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Food and Agriculture Tech. Most recently it participated in the $***** Series B round of EpiBiologics Overall, Codon Capital portfolio has seen 1 unicorn, 7 IPOs and 8 acquisitions including key companies like RAPT, Kura Oncology and Vaxart. A lot of funds co-invest with Codon Capital, with names like Digitalis Ventures sharing a substantial percentage of its portfolio.Key Metrics
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 1 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Deals in last 12 months
Codon Capital's List of Top Investments
Codon Capital has a portfolio of 31 companies, one of which is a Unicorn. Their most notable investmentis in EpiBiologicsTheir portfolio spans across and United States. They have invested in Life Sciences, High Tech, Food and Agriculture Tech and 7 other sectors, across stages such as Series A, Series B and 1 more. Here is the list of top investments by Codon Capital:1. Antheia
Antheia is focused on developing medicines using its technology. Its technology combines synthetic biology, informatics, and fermentation technology to provide plant-based medicines. It is currently working on engineering the yeast cells genetically to produce natural medicinal products.
Key facts about Antheia
- Founded Year: 2013
- Location: Palo Alto (United States)
- Stage: Series C
- Total Funding till date: $176M
- Employee Count: 71 as on Sep 30, 2026
- Investors: Sherpalo Ventures, SVB and 15 Others
- Latest Funding Round: Series C, Jan 27, 2026, $*****
- Highlight: Editors' Pick
2. eGenesis
Developer of a gene transplantation platform for humanizing pig cells. The company has developed a technology to humanize pig cells that will grow into human-compatible organs. These organs will be harvested in the donor pig and safely transplanted to human patients. The company's technology is based on the next-generation genome engineering toolset and CRISPR.
Key facts about eGenesis
- Founded Year: 2015
- Location: Cambridge (United States)
- Valuation: $*****
- Stage: Series D
- Total Funding till date: $495M
- Employee Count: 153 as on Sep 30, 2026
- Investors: SymBiosis, Monashee Investment Management and 31 Others
- Latest Funding Round: Series D, Aug 25, 2026, $*****
- Highlight: Editors' Pick
3. RAPT
Rapt is a biopharmaceutical drug developer for oncology and inflammatory diseases based on immunology. It offers its proprietary drug discovery and development platform for small molecules to modulate the immune responses targeting CCR4 (C-C motif chemokine receptor 4). The lead drug candidate of the company is, FLX475 is in phase 1 of the clinical trial, RPT193 in the pre-clinical stage. The company also provides other targets including GCN2 (general control nonderepressible 2) and HPK1 (hematopoietic progenitor kinase 1) for the treatment of cancer.
Key facts about RAPT
- Founded Year: 2015
- Location: San Francisco (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $199M
- Employee Count: 120 as on Sep 30, 2026
- Investors: RTW Investments, BVF Partners and 19 Others
- Latest Funding Round: Post IPO, Dec 23, 2024, $*****
- Highlight: Acquired
Kura Oncology develops targeted small molecule drugs for solid tumours and blood cancer. It's lead candidate tipifarnib, a farnesyl transferase inhibitor, is in Phase II trials for HRAS positive solid tumours and peripheral T-cell lymphomas and has completed phase I trials for myelodysplastic syndrome. In addition, the company is also investigating an ERK inhibitor and Menin MLL inhibitors.
Key facts about Kura Oncology
- Founded Year: 2014
- Location: San Diego (United States)
- Stage: Public
- Total Funding till date: $63.4M
- Employee Count: 320 as on Sep 30, 2026
- Investors: Foresite Capital, Fidelity Investments and 10 Others
- Latest Funding Round: Post IPO, Jan 26, 2024, $*****
- Highlight: Public
Provider of DNA synthesis technology using enzymes. The company offers a chemical method and Next-generation technology for synthesis. Their technology is based on polymerase-nucleotide conjugates that have the ability to extend a DNA molecule by one building block at a time.
Key facts about Ansa Biotechnologies
- Founded Year: 2017
- Location: Berkeley (United States)
- Valuation: $*****
- Stage: Series B
- Total Funding till date: $177M
- Employee Count: 81 as on Sep 30, 2026
- Investors: RA Capital Management, Mubadala and 17 Others
- Latest Funding Round: Series B, Oct 02, 2025, $*****
- Highlight: Editors' Pick
Codon Capital's Year-on-Year Investment Trends
Codon Capital has invested in 31 companies over the last 12 years, with an average of 1 new investment annually in the last 10 years. As of Jan 2026, it has made 1 investment in this year. Its most recent first time investment was in Seismic and most recent follow-on round was in EpiBiologics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 1 | 1 |
2025 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 3 | 0 | 3 |
2022 | 2 | 0 | 2 |
2021 | 0 | 0 | 0 |
2020 | 2 | 0 | 2 |
Codon Capital's Investments by Stage
Codon Capital has made 5 investments in Series A stage with an average round size of $47.3M, 2 investments in Series B stage with an average round size of $93.1M and 1 investment in Series C stage with an average round size of $100M.Stage of entry | No. of Investments |
|---|---|
Series A | 5 |
Series B | 2 |
Series C | 1 |
Note: We have considered here, only first round of investments
Codon Capital's Investments by Sector
Codon Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech, Chemicals and Materials Tech and Consumer. Notably, it has invested in 30 Tech companies, 27 Enterprise (B2B) companies, 2 Social impact companies and at least 2 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 7 |
High Tech | 4 |
Sustainability Tech | 2 |
Chemicals and Materials Tech | 1 |
Consumer | 1 |
Others | 4 |
Note: We have considered here, only first round of investments
Codon Capital's Investments by Geography
Codon Capital has made most investments in United States (8).Codon Capital's recent investments
Codon Capital has made 1 investments in 2026 so far - EpiBiologics.Here are the most recent investments by Codon Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 08, 2026 | United States | Series B | 4751 | [+10] | |
Nov 17, 2023 | United States | Series B | 1613 | ||
Sep 19, 2023 | United States | Series A | 2202 | ||
Jul 20, 2023 | United States | Series A | 6030 | [+5] | |
Nov 15, 2022 | United States | Series A | 7351 | [+4] |
Unicorns in Codon Capital's Portfolio
Codon Capital has 1 unicorn in its portfolio - Pivot Bio. The most recent unicorn in their portfolio is Pivot Bio which became a unicorn in 2021, 1 years after Codon Capital first invested in it.Here is a list of unicorns in Codon Capital's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
58 | Developer of microbial nitrogen products designed for crop nutrition enhancement | 2010 | Berkeley | Series D | dspstug |
IPOs and Publicly Listed companies in Codon Capital's Portfolio
7 of Codon Capital's portfolio companies have become public. Caribou Biosciences got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jul 2021 at marketcap of $907M and Bolt Threads got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are Codon Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 23, 2021 | - | - | 2890 | |
May 07, 2021 | Apr 11, 2014 | Series B | 1148 | |
Oct 09, 2020 | - | - | 7731 | |
Apr 24, 2020 | - | - | 8304 | |
Mar 15, 2018 | - | - | 3360 |
Acquired companies in Codon Capital's Portfolio
8 companies from Codon Capital's portfolio have been acquired. The most recent acquisition was RAPT in Jan 2026 by GSK for $*****.Here are Codon Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jan 20, 2026 | - | - | 6329 | |
Sep 07, 2022 | May 21, 2020 | Series A | 4832 | |
Jul 25, 2022 | - | - | 3951 | |
Apr 28, 2021 | - | - | 8989 | |
Jul 17, 2018 | - | - | 5873 |
Co-investors of Codon Capital
Over the past 12 years, 83 investors have co-invested in Codon Capital's portfolio companies. This includes funds and angels.
- Invested before Codon Capital: Mubadala, America’s Seed Fund and 19 others have invested in rounds before Codon Capital. There are 2 companies where Mubadala has invested before Codon Capital and 2 companies where America’s Seed Fund has invested before Codon Capital.
- Top Co-investors of Codon Capital: 35 investors entered a company along with Codon Capital. These include investors like Digitalis Ventures (3 companies).
- Invested after Codon Capital: A total of 27 investors have invested in Codon Capital's portfolio after their investments. Top Investors include Cerberus Capital Management (1 company), Blue Water Life Science Advisors (1 company) and Fall Line Capital (1 company).
Recent News related to Codon Capital
•
•
Seismic Therapeutic Closes $121M Series B FinancingFinSMEs•Dec 04, 2023•Seismic, Bessemer Venture Partners, Amgen, Codon Capital and 7 others
•
•
Seattle biotech startup born out of a Roche buyout lands $93M to advance therapiesGeekWire•Nov 15, 2022•Bonum Therapeutics, RiverVest Venture Partners, Roche, Digitalis Ventures and 3 others
•
•
Good Therapeutics raises $11M to develop ‘context dependent’ protein drugsGeekWire•May 21, 2020•Good Therapeutics, Roche, RiverVest Venture Partners, 3x5 Partners and 2 others
•
Pivot Bio Raises Additional $100 Million To Transform Agriculture EconomicsGlobeNewswire•Apr 30, 2020•Pivot Bio, Breakthrough Energy, Temasek, DCVC and 8 others
